Dynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 43.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 53,566 shares of the biopharmaceutical company’s stock after buying an additional 16,186 shares during the quarter. Intech Investment Management LLC’s holdings in Dynavax Technologies were worth $684,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Dynavax Technologies during the 4th quarter worth $71,000. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,076 shares in the last quarter. Finally, KBC Group NV increased its holdings in Dynavax Technologies by 68.7% in the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 2,857 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th.

Dynavax Technologies Stock Up 1.5 %

Dynavax Technologies stock opened at $13.82 on Monday. The company has a market capitalization of $1.71 billion, a P/E ratio of 76.78 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The stock has a 50-day simple moving average of $13.22 and a 200-day simple moving average of $12.41.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Equities research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.